James Condulis
Stock Analyst at Stifel Nicolaus
(2.99)
# 2,591
Out of 4,408 analysts
44
Total ratings
57.9%
Success rate
5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics | Downgraded: Hold | $25 → $3 | $3.51 | -14.53% | 5 | Jun 2, 2026 | |
| EWTX Edgewise Therapeutics | Maintained: Hold | n/a | $35.21 | - | 5 | Jun 1, 2026 | |
| TECX Tectonic Therapeutic | Maintained: Buy | $75 | $29.39 | +155.19% | 2 | May 8, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $130 → $136 | $101.00 | +34.65% | 7 | May 7, 2026 | |
| CYTK Cytokinetics | Rated: Buy | $98 → $108 | $71.38 | +51.30% | 15 | May 6, 2026 | |
| AMLX Amylyx Pharmaceuticals | Initiated Coverage: Buy | $21 | $15.19 | +38.25% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgraded: Hold | $24 → $6 | $3.84 | +56.25% | 4 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Buy | $50 | $30.60 | +63.40% | 4 | Feb 6, 2026 | |
| XFOR X4 Pharmaceuticals | Initiated Coverage: Buy | $10 | $4.08 | +145.10% | 1 | Dec 5, 2025 |
Fulcrum Therapeutics
Jun 2, 2026
Downgraded: Hold
Price Target: $25 → $3
Current: $3.51
Upside: -14.53%
Edgewise Therapeutics
Jun 1, 2026
Maintained: Hold
Price Target: n/a
Current: $35.21
Upside: -
Tectonic Therapeutic
May 8, 2026
Maintained: Buy
Price Target: $75
Current: $29.39
Upside: +155.19%
Mirum Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $130 → $136
Current: $101.00
Upside: +34.65%
Cytokinetics
May 6, 2026
Rated: Buy
Price Target: $98 → $108
Current: $71.38
Upside: +51.30%
Amylyx Pharmaceuticals
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $15.19
Upside: +38.25%
Aardvark Therapeutics
Mar 2, 2026
Downgraded: Hold
Price Target: $24 → $6
Current: $3.84
Upside: +56.25%
NewAmsterdam Pharma Company
Feb 6, 2026
Maintained: Buy
Price Target: $50
Current: $30.60
Upside: +63.40%
X4 Pharmaceuticals
Dec 5, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $4.08
Upside: +145.10%